ライフサイエンスコーパス: alendronate

1 ower mean BMD before ADT, or a lower cost of alendronate.

2 luate the efficacy and safety of (64)Cu-DOTA-alendronate.

3 mab compared with those receiving placebo or alendronate.

4 ity that is greater than in those continuing alendronate.

5 raloxifene (HR, 1.18 [CI, 0.96 to 1.46]) and alendronate.

6 ceiving teriparatide than in those receiving alendronate.

7 prevented and improved with once-weekly oral alendronate.

8 e continuing (19%) and discontinuing (18.9%) alendronate.

9 fractures compared with those who continued alendronate.

10 n-7-ol (EM652), and the aminobisphosphonate, alendronate.

11 ectomized animals treated with E2, EM652, or alendronate.

12 e of synergy between parathyroid hormone and alendronate.

13 one-induced stimulation of bone formation by alendronate.

14 ed pharmacologically with the bisphosphonate alendronate.

15 s of age and had low bone density to receive alendronate (10 mg daily; 28 men), parathyroid hormone (

16 nts were randomly assigned to receive either alendronate (10 mg per day) or calcitriol (0.5 microg pe

17 trolled, randomized, double-blinded trial of alendronate (10 mg/day orally) (n = 24) compared with pl

18 roid hormone (1-84) (100 microg; 119 women), alendronate (10 mg; 60 women), or both (59 women) and we

19 as B3, in femurs of adult mice injected with alendronate (10 microg/100 g/wk) for 8 weeks.

20 r without medroxyprogesterone, 2.5 mg/d) and alendronate, 10 mg daily, both agents, or neither.

21 2 years of therapy with alendronate, 10 mg/d (n = 92); conjugated estrogen, 0.62

22 were oral bisphosphonate users at entry (90% alendronate, 10% etidronate).

23 intestinal tract symptoms (alendronate vs no alendronate, 15.6 [95% CI, 11.6-21.0] vs 12.9 [95% CI, 9

24 is there were 133 cases of AMD reported with alendronate, 20 with ibandronate, and 14 with risedronat

25 In all, 75 subjects (34 alendronate, 25 calcitriol, 16 reference) participated.

26 Liposomal alendronate (3 or 6 mg/kg) was given concurrently with s

27 le-blind, 2-arm, placebo-controlled trial of alendronate (40 mg/d) was performed in adults with GD wh

28 Randomization to alendronate, 5 mg/d (n = 329) or 10 mg/d (n = 333), or p

29 served more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 p

30 rs of bone turnover compared with continuing alendronate: 55.6% (P<.001) for C-telopeptide of type 1

31 al year with either placebo (60 subjects) or alendronate (59 subjects).

32 ncer receiving ADT were randomly assigned to alendronate 70 mg once weekly or placebo in a double-bli

33 bo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparatide

34 utaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months,

35 of monthly ibandronate (150 mg) with weekly alendronate (70 mg) were compared in a randomized, 2-yea

36 Our hypothesis is that alendronate, a member of the N-containing bisphosphonate

37 nylalkyl) derivatives of pamidronate and one alendronate, a molecular field analysis (MFA) yielded an

38 thylene glycol (PEG), and bisphosphonate (or alendronate, a targeting ligand).

39 sulated alendronate (PLN-alen), but not free alendronate, abrogated PLN-induced tumor growth and incr

40 (CM) collected from osteocytes treated with alendronate (AD), a bisphosphonate drug, inhibited the m

41 zed a novel, fluorescently labeled analog of alendronate (AF-ALN).

42 Women who discontinued alendronate after 5 years showed a moderate decline in B

43 acilities; 1802 patients who were prescribed alendronate after at least 3 months of oral prednisolone

44 as been fabricated for controlled release of alendronate (AL).

45 (N-BP), including zoledronic acid (ZOL) and alendronate (ALD), have been proposed as sensitisers in

46 icated a functionalized GNPs conjugated with alendronate (ALD), of the bisphosphonate group.

47 eta1 on the MSC surface to a bisphosphonate (alendronate, Ale) that has a high affinity for bone.

48 aims to explore the clinical efficacy of 1% alendronate (ALN) gel as a local drug delivery system in

49 The response of osteoclasts to alendronate (ALN) in tumor necrosis factor-transgenic (T

50 Alendronate (ALN) increases alveolar bone density with s

51 Alendronate (ALN) is an antiresorptive agent widely used

52 The traditional bisphosphonate (BP) alendronate (Aln) or IG9402, a BP analog that does not i

53 he treatment of bisphosphonate drugs, either alendronate (ALN) or zoledronic acid (ZOL), opened Cx43

54 Alendronate (ALN), a member of the amino-bisphosphonate

55 LT) model of OA and evaluated the effects of alendronate (ALN), a potent inhibitor of bone resorption

56 Alendronate (ALN), an aminobisphosphonate, is known to i

57 Alendronate (ALN), an aminobisphosphonate, is known to s

58 Alendronate (ALN), an influential member of the bisphosp

59 onth periods without parathyroid hormone, or alendronate alone for 15 months.

60 n bone mass at the hip in women treated with alendronate alone were significantly greater than in tho

61 ull-length parathyroid hormone (1-84) alone, alendronate alone, or both combined.

62 a significantly lower risk of fracture than alendronate alone.

63 ssion and tumor growth can be reversed using alendronate, an immune modulatory drug.

64 compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo).

65 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide.

66 ompared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and

67 ompared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at

68 s in fracture risk reduction attributable to alendronate and alendronate cost.

69 the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and a

70 ort of 108 participants in a trial comparing alendronate and calcitriol for prevention of posttranspl

71 chemo-immunotherapy strategies to co-deliver alendronate and chemotherapy for the treatment of cancer

72 ; conjugated estrogen, 0.625 mg/d (n = 143); alendronate and conjugated estrogen (n = 140); or placeb

73 s not cost-effective, assuming U.S. costs of alendronate and currently available estimates of alendro

74 ocalcification targeting specificity of DOTA-alendronate and elucidate the histologic and ultrastruct

75 Combination therapy with alendronate and estrogen for 2 years increases bone mine

76 Elderly women being treated with alendronate and estrogen had a significantly decreased p

77 teoprotegerin, and the amino bisphosphonates alendronate and ibandronate.

78 Both regimens, weekly alendronate and monthly ibandronate, improve bone mass a

79 e was 0.068 +/- 0.21 and 0.015 +/- 0.034 for alendronate and placebo groups, respectively (P =.001).

80 Men initially randomly assigned to alendronate and randomly reassigned at year 2 to continu

81 Bisphosphonates such as alendronate and zoledronate are blockbuster drugs used t

82 irtually abolished by OPG treatment, whereas alendronate and zoledronate only partially reduced these

83 We used bisphosphonate inhibitors, alendronate and zoledronate, that inhibit the consumptio

84 Mice were treated with prednisolone, alendronate, and both in combination for up to 6 months.

85 5 to 0.913 +/- 0.026 g/cm(2), P < 0.001 with alendronate, and from 0.898 +/- 0.024 to 0.949 +/- 0.027

86 ystemic disease was managed with prednisone, alendronate, and losartan.

87 Src inhibitor dasatinib, the bisphosphonate alendronate, and the osteoclast-specific apoptosis-induc

88 Although in this study oral alendronate appears to be well tolerated in patients wit

89 ed with alendronate; when women treated with alendronate are switched to denosumab, there is an incre

90 se of this study was to evaluate (64)Cu-DOTA-alendronate as a mammary microcalcification-targeting PE

91 groups: those receiving placebo for 3 years; alendronate at a dose of 1, 5, or 10 mg per day for 3 ye

92 se of 1, 5, or 10 mg per day for 3 years; or alendronate at a dose of 20 mg per day for 2 years, foll

93 n increase compared with those who initiated alendronate at baseline.

94 ralized and demineralized bone was soaked in alendronate at concentrations of 0.002, 2.0, and 2,000 n

95 ronate use; no patients had previously taken alendronate at the time of prednisolone initiation.

96 The clinical findings that alendronate blunted the anabolic effect of human parathy

97 In men treated with alendronate, bone mineral density increased over 1 year

98 ns appear to be maintained or increased with alendronate but lost if parathyroid hormone is not follo

99 Use of alendronate, but not estrogen, was associated with less

100 oaked mineralized bone contained measureable alendronate, but the substance was removed by deminerali

101 Biodistribution studies revealed tissue alendronate concentrations peaking within the first hour

102 Confocal analysis with carboxyfluorescein-alendronate confirmed the microcalcification binding spe

103 formulation by co-packaging DAC and ATO into alendronate-conjugated bone-targeting nanoparticles (BTN

104 of the synthesized polymers: PLGA-b-PEG and alendronate-conjugated polymer PLGA-b-PEG-Ald, which ens

105 sk reduction attributable to alendronate and alendronate cost.

106 ethanol (SIM-EtOH); 2) 0.5 mg simvastatin in alendronate-cyclodextrin conjugate (SIM-ALN-CD); 3) EtOH

107 10), women who had received 5 mg or 10 mg of alendronate daily continued on the same treatment.

108 Treatment with 10 mg of alendronate daily for 10 years produced mean increases i

109 the discontinuation group received 20 mg of alendronate daily for two years and 5 mg daily in years

110 An investigation of the chemical behavior of alendronate derivatives led to development of practical

111 Alendronate derivatives were evaluated as potential prod

112 he microcalcification binding specificity of alendronate derivatives.

113 similar in both groups and one patient with alendronate developed a new vertebral fracture.

114 n of pre-osteoclasts from bone marrow cells, alendronate did not affect osteoblast differentiation, i

115 active-treatment groups continued to receive alendronate during the initial extension (years 4 and 5)

116 dronate and currently available estimates of alendronate efficacy in osteopenic women.

117 Prednisolone alone and in combination with alendronate enhance functionally glycosylated alpha-dyst

118 Good evidence suggests that alendronate, etidronate, ibandronate, risedronate, zoled

119 Men receiving alendronate for 2 years experienced a mean 6.7% (+/- 1.2

120 women with osteoporosis who had been taking alendronate for at least 1 year to continued alendronate

121 Our long-term goal is to develop (64)Cu-DOTA-alendronate for the detection and noninvasive differenti

122 Herein, we evaluated prednisolone and alendronate for their therapeutic potential in the FKRPP

123 ate cancer, a BMD test followed by selective alendronate for those with osteoporosis is a cost-effect

124 al women with osteoporosis were treated with alendronate for up to 10 years.

125 gest that for many women, discontinuation of alendronate for up to 5 years does not appear to signifi

126 atients taking oral bisphosphonates, such as alendronate, for osteoporosis is uncertain and warrants

127 whether the demineralization process removes alendronate from allograft bone.

128 ization process effectively removed residual alendronate from allograft bone.

129 (P = .005) in spine BMD was observed in the alendronate group (0.09 +/- 0.03 g/cm2 SD from baseline)

130 curred in the teriparatide group than in the alendronate group (0.6% vs. 6.1%, P=0.004); the incidenc

131 f 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 patients]) (P<0.00

132 alendronate group than in the alendronate-to-alendronate group (178 of 2046 patients [8.7%] vs. 217 o

133 fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 patients]) than in

134 d more in the teriparatide group than in the alendronate group (7.2+/-0.7% vs. 3.4+/-0.7%, P<0.001).

135 triol group (P< or =0.001) and by 32% in the alendronate group (P< or =0.001).

136 in the parathyroid hormone group than in the alendronate group (P<0.001) or the combination-therapy g

137 in the combination-therapy group than in the alendronate group (P<0.001).

138 lcitriol group and 7 percent of those in the alendronate group (P=0.01).

139 ad decreased by a mean of 0.7 percent in the alendronate group and 1.6 percent in the calcitriol grou

140 ck decreased by a mean of 1.7 percent in the alendronate group and 2.1 percent in the calcitriol grou

141 4 years), there were 27 hip fractures in the alendronate group and 73 in the no-alendronate group, co

142 rathyroid hormone group as compared with the alendronate group and no significant difference between

143 ase of 31 percent in the parathyroid hormone-alendronate group as compared with 14 percent in the par

144 in the cyclic-therapy group, and four in the alendronate group had new or worsening vertebral deformi

145 in the parathyroid hormone group than in the alendronate group or the combination-therapy group (P<0.

146 tures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate

147 f 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in

148 icantly among the groups (6.8 percent in the alendronate group, 3.6 percent in the calcitriol group,

149 s, 14 in the ibandronate group and 19 in the alendronate group, completed the trial.

150 es in the alendronate group and 73 in the no-alendronate group, corresponding to incidence rates of 9

151 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with ro

152 sed in the combination-therapy group and the alendronate group.

153 percent (P=0.03 for the comparison with the alendronate group; P=0.15 for the comparison with the ca

154 omosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 eve

155 Similarly, those discontinuing alendronate had increased serum markers of bone turnover

156 hic cardiac calcification phenotype, whereas alendronate had no significant effect.

157 nts with osteoporosis treated with long-term alendronate have a response to parathyroid hormone treat

158 nvertebral fractures than those who received alendronate (HR, 1.40, [CI, 1.20 to 1.63]).

159 The reported odds ratios (RORs) for alendronate, ibandronate, and risedronate were 3.82 (95%

160 dications are for treatment of osteoporosis (alendronate, ibandronate, and risedronate) and treatment

161 Alendronate impairs the ability of parathyroid hormone t

162 c prostate cancer receiving ADT, once-weekly alendronate improves bone density and decreases turnover

163 Once-weekly alendronate improves bone mass and is well tolerated in

164 ion initiators: a study of raloxifene versus alendronate in 1-year nonvertebral fracture risk, a stud

165 trolled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages

166 developed and validated to quantify residual alendronate in allograft bone.

167 ashion for 12 months, followed by open-label alendronate in both groups.

168 rats showed specific binding of (64)Cu-DOTA-alendronate in mammary glands and mammary tumors.

169 Encapsulating alendronate in PLN reversed these effects on myeloid cel

170 of events, these results support the use of alendronate in this patient group.

171 (control) or diets containing etidronate or alendronate in three different concentrations (experimen

172 Patients randomly assigned to begin alendronate in year 2 experienced improvements in bone m

173 dronate monotherapy in year 1 continued with alendronate in year 2.

174 eived combination therapy in year 1 received alendronate in year 2; those who had received alendronat

175 Women in the original placebo group received alendronate in years 4 and 5 and then were discharged.

176 Alendronate increased BMD at both the spine and hip in e

177 We found that alendronate increased gene and protein expression of eph

178 the highly specific pharmaceutical inhibitor alendronate inhibited beta2AR down-regulation.

179 ne-targeted antiresorptives bis-enoxacin and alendronate inhibited increases in oxidative stress caus

180 Conclusion:(64)Cu-DOTA-alendronate is a promising PET imaging agent for the sen

181 Alendronate is a useful adjunctive therapy in combinatio

182 in vitro and in vivo studies that liposomal alendronate (L-ALD) can sensitise cancer cells to destru

183 l oxide surface and the phosphate residue of alendronate, leading to formation of homogenous drug dis

184 of oral bisphosphonate use were compared to alendronate levels in DBM procured from donors without a

185 Alendronate levels in DBM procured from tissue donors wi

186 turnover suggest that the concurrent use of alendronate may reduce the anabolic effects of parathyro

187 Although it has been suggested that alendronate might improve bone mineral density (BMD) in

188 lendronate in year 2; those who had received alendronate monotherapy in year 1 continued with alendro

189 levels in calcitriol-treated patients makes alendronate more attractive for the prevention of bone l

190 icate stronger suppressive effects of E2 and alendronate on bone formation activity and that ovariect

191 r systemically applied antiresorptive agent (alendronate) on simvastatin-induced bone formation in an

192 ratide once daily, and 214 received 10 mg of alendronate once daily.

193 of 14, 60, 100, or 210 mg), open-label oral alendronate once weekly (at a dose of 70 mg), or placebo

194 Furthermore, osteoclasts treated with alendronate or alphav reduced the formation of the seali

195 viously reported that subjects randomized to alendronate or calcitriol immediately after cardiac tran

196 on, we evaluated the effect of discontinuing alendronate or calcitriol on bone loss and biochemical m

197 bjects who completed the randomized trial on alendronate or calcitriol, and in reference subjects who

198 After discontinuing alendronate or calcitriol, BMD remained stable during th

199 were randomized to receive 70 mg per week of alendronate or placebo over 1 year.

200 n the ORs estimated according with BPs type (alendronate or risedronate) and regimen (daily or weekly

201 sed pharmaceutical inhibitors, atorvastatin, alendronate or zaragozic acid to inhibit the activity of

202 onate but prevented the inhibitory effect of alendronate or zoledronate on Rap1A prenylation.

203 s greatly decreased by OPG but not by either alendronate or zoledronate.

204 nefits are retained after discontinuation of alendronate or zoledronic acid, drug holidays after 5 ye

205 aneous injections of enoxacin, bis-enoxacin, alendronate, or doxycycline were administered for 6 week

206 fter treatment of animals with vehicle, OPG, alendronate, or zoledronate.

207 046) was also observed in the femoral BMD of alendronate patients versus placebo.

208 factor of 2.6 in patients receiving 10 mg of alendronate per day for 3 years as compared with the pla

209 During the open-label alendronate period, adjudicated events of osteonecrosis

210 l, run-in phase with hormone replacement and alendronate placebo.

211 rtantly, we also found that PLN-encapsulated alendronate (PLN-alen), but not free alendronate, abroga

212 alendronate for at least 1 year to continued alendronate plus parathyroid hormone (1-34) subcutaneous

213 rmone (1-34) subcutaneously daily, continued alendronate plus parathyroid hormone (1-34) subcutaneous

214 Alendronate produced greater decreases from baseline in

215 Combined treatment of prednisolone and alendronate provided best improvement in muscle patholog

216 A second year of alendronate provides additional skeletal benefit, wherea

217 isk for nonvertebral fractures compared with alendronate recipients.

218 (HR, 1.78 [CI, 1.20 to 2.63]) compared with alendronate recipients.

219 < 0.05), whereas E2, raloxifene, EM652, and alendronate regulated 613, 765, 652, and 737 probe sets,

220 tives of this study are to determine whether alendronate remained in demineralized bone matrix (DBM)

221 The discontinuation of alendronate resulted in a gradual loss of effect, as mea

222 osozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fr

223 .8] vs 3.0% [4.9]; P<.05, respectively), and alendronate resulted in more responders to therapy.

224 The discontinuation of alendronate resulted in the gradual loss of its effects.

225 hours after a single injection of liposomal alendronate, returning to basal levels at 6 days.

226 Good evidence suggests that alendronate, risedronate, and estrogen prevent hip fract

227 linicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab

228 ral fractures (5.3% for placebo and 2.4% for alendronate; RR, 0.45; 95% CI, 0.24-0.85) but no signifi

229 al fractures (11.3% for placebo and 9.8% for alendronate; RR, 0.86; 95% CI, 0.60-1.22).

230 indicating the need for pre-osteoclasts for alendronate's effects.

231 study assesses the effects of topical sodium alendronate (SA) as an adjuvant to the mechanical treatm

232 In-vitro studies showed that alendronate SAMs induce differentiation of hMSC to a bon

233 ion, in patients with PBC-related bone loss, alendronate significantly improves BMD compared with pla

234 The use of alendronate significantly mitigated the bone loss.

235 potential prodrugs for the osteoporosis drug alendronate sodium in an attempt to enhance the systemic

236 detected in any of the DBM samples soaked in alendronate solutions.

237 Alendronate stimulated EphB1 and EphB3 protein expressio

238 eficient receptor down-regulation induced by alendronate, suggesting that FDPS regulates receptor dow

239 In addition, E2 and alendronate suppressed a cluster of genes associated wit

240 Alendronate suppressed the expression of bone sialoprote

241 Compared with continuing alendronate, switching to placebo for 5 years resulted i

242 te for at least 3 years before screening and alendronate the year before screening; an areal BMD T sc

243 Over two years, alendronate therapy after parathyroid hormone therapy le

244 for the strategy of a BMD test and selective alendronate therapy for patients with osteoporosis and u

245 te therapy, a BMD test followed by selective alendronate therapy for patients with osteoporosis, or u

246 Alendronate therapy for postmenopausal women with femora

247 sity (BMD) before initiating ADT followed by alendronate therapy in men with localized prostate cance

248 edronic acid, drug holidays after 5 years of alendronate therapy or 3 years of zoledronic acid therap

249 Five years of alendronate therapy or no drug treatment.

250 Alendronate therapy was given for 30 months; parathyroid

251 The ICER for universal alendronate therapy without a BMD test decreased to $100

252 for patients with osteoporosis and universal alendronate therapy without a BMD test were $66,800 per

253 for patients with osteoporosis, or universal alendronate therapy without a BMD test.

254 No BMD test or alendronate therapy, a BMD test followed by selective al

255 Thus, alendronate, through its direct effects on the pre-osteo

256 acebo-controlled, dose-ranging trial of oral alendronate to prevent bone resorption among healthy pos

257 vidence is lacking regarding the efficacy of alendronate to protect against hip fracture in older pat

258 nd clinical study of parathyroid hormone and alendronate to test the hypothesis that the concurrent a

259 up (6.2% [127 of 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 pat

260 romosozumab-to-alendronate group than in the alendronate-to-alendronate group (178 of 2046 patients [

261 p versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% low

262 t each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral

263 The alendronate-treated patients gained (mean +/- SD) 4.9 +/

264 Alendronate-treated patients sustained less bone loss at

265 Alendronate treatment did not ameliorate muscle degenera

266 , the physiological target of beta-agonists, alendronate treatment functionally reversed agonist-indu

267 clasts with 20 to 40 nuclei were found after alendronate treatment had been discontinued for 1 year.

268 To investigate whether alendronate treatment in older patients using oral predn

269 Long-term alendronate treatment is associated with an increase in

270 using medium to high doses of prednisolone, alendronate treatment was associated with a significantl

271 Alendronate treatment was not associated with increased

272 nts with persistent osteoporosis after prior alendronate treatment, both daily treatment and cyclic t

273 Conversely, alendronate treatment, which restricts osteoclast activi

274 Both alendronate use and estrogen use were associated with si

275 ing was used to select 1802 patients without alendronate use from 6076 patients taking prednisolone w

276 confidence interval [CI], 0.06 to 16.46) for alendronate use in the FIT trial, 1.50 (95% CI, 0.25 to

277 d 1.33 (95% CI, 0.12 to 14.67) for continued alendronate use in the FLEX trial.

278 Alendronate use was also associated with a reduction in

279 Alendronate vs no alendronate use; no patients had previously taken alendr

280 l4V alloy by chemisorption of osseoinductive alendronate using a simple, effective and clean methodol

281 of this study was to compare the effects of alendronate versus placebo on BMD and biochemical measur

282 Alendronate vs no alendronate use; no patients had previ

283 mild upper gastrointestinal tract symptoms (alendronate vs no alendronate, 15.6 [95% CI, 11.6-21.0]

284 The use of alendronate was associated with a lower risk of hip frac

285 ination therapy with hormone replacement and alendronate was efficacious and well tolerated in this c

286 The highest uptake of (64)Cu-DOTA-alendronate was in malignant tumors and the lowest uptak

287 Alendronate was more effective than placebo in improving

288 Residual alendronate was not detected in the DBM from either grou

289 Results:(64)Cu-DOTA-alendronate was radiolabeled with a 98% yield.

290 Alendronate was superior to hormone replacement, and com

291 DOTA-alendronate was synthesized, radiolabeled with (64)Cu, a

292 Alendronate was the reference category in all analyses.

293 e risk between risedronate or raloxifene and alendronate were small.

294 The therapeutic effects of alendronate were sustained, and the drug was well tolera

295 ction in bone turnover markers compared with alendronate; when women treated with alendronate are swi

296 tibiotic activities, was more effective than alendronate, which acts only as an antiresorptive.

297 hypothesized that subjects who discontinued alendronate, which has a long half-life in bone, would n

298 We conducted a randomized trial comparing alendronate with calcitriol for the prevention of bone l

299 e of the study compared three daily doses of alendronate with placebo.

300 Routine use of alendronate without a BMD test is justifiable in patient

301 ements of side-chain 2H-labeled pamidronate, alendronate, zoledronate, and risedronate on bone show t